Genentech's TIGIT-targeted antibody tiragolumab missed its endpoints in two late-stage lung cancer trials, raising doubts about one of the most widely studied next-generation checkpoint targets in immuno-oncology. But numerical signs of benefit among certain patients with metastatic non–small cell lung cancer suggest that TIGIT blockade still has potential—if drug developers can successfully identify the best indications, drug combinations, or patient populations.

You do not currently have access to this content.